Latest Research On Alzheimer’s Disease Comes Out to Be Fraud


Scientists claim that some part of the recent research on Alzheimer’s disease has been manipulated. The detailed report is published in the journal Science.

Alzheimer’s disease happens to be the most common cause of dementia, as per the data suggested by WHO. The original paper published in the year 2006 guided hundreds of dollars in the US federal government research.

The results were established after performing a clinical study in mice. During the test, it was detected cognitive decline in mice.

Since then the above hypothesis started dominating the entire world. Researchers are working for decades to basically understand the entire mechanism to know the cause of the decline of such proteins.


Also Read: Blueberries Known to Prevent Dementia Among Middle Aged People


But a neuroscientist has claimed that he and some other researchers have worked for years and have even identified up to 10 proteins that need to be given a deeper scrutiny.

The same researchers also took the help of some other prominent researchers who had issues to replicate the results of their studies on the above proteins.

The researcher says, “I focus on what we can see in the published images, and describe them as red flags, not final conclusions,” he told Science, when revealing his role as a whistleblower. “The data should speak for itself.” he said.

On the other hand scientists have been working hard for decades to get a breakthrough in treating Alzheimer’s disease.

Although, a drug is available to treat the early stages of Alzheimer’s disease, only one drug has so far been approved by the FDA (US Food and Drug Administration).

The drug named Aduhelm is known to treat the protein plaques thay are associated with Alzheimer’s aducanumab.

The above drug Aduhelm is basically developed by Biogen. Even before the manufacturers of this drug were expecting to be approved by the FDA in 2021, some leading FDA officials stated that it has no proof to actually benefit the ailing patient.

Even then, the agency approved the drug, which Biogen priced at $56,000. And that finally prompted the resign of 3 FDA officials.

As per the data shared by the National Institute on Aging, as many as 3 million Americans are detected with Alzheimer’s disease.

The Alzheimer’s Society says that over 8 lakh people in the UK become prey to dementia.


Also Read: Multiple Heart Related Conditions Linked To Triple Dementia Risk